Status:
COMPLETED
A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
HIV Infections
Acquired Immunodeficiency Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a study that will investigate the safety and efficacy of an investigational drug in Human immunodeficiency virus (HIV) infected patients.
Detailed Description
Participants who completed 48 weeks of the original 48-week double-blind study were invited to continue in two extensions: MK0518-004-10 (NCT00100048), which extended the study to 144 weeks, and MK051...
Eligibility Criteria
Inclusion
- Patient must be HIV positive who must have received less than 7 days total of any antiretroviral therapy (HIV related therapy)
- Extension Studies:
- First extension: Patient completed the 48-week base study
- Second extension: Patient completed the first 144-week extension study
Exclusion
- Less than 18 years of age
- Individuals who currently do not test positive for HIV
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
206 Patients enrolled
Trial Details
Trial ID
NCT00100048
Start Date
January 1 2005
End Date
July 1 2010
Last Update
September 9 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.